A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

• Sponsor: Galecto Biotech AB (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03809052
• Collaborator: (none)
• Enrollment: 78
• Location: 1
• Arms: 11
• Actual Duration (Months): 5.3
• Patients Per Site Per Month: 14.7

Study Details

Study Description

Brief Summary

This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult subjects with indication of suspected Nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Condition or Disease	Intervention/Treatment	Phase
Safety and Tolerability	Drug: GB1211; Drug: Placebo	Phase 1

Detailed Description

The study consisted of 2 parts: a SAD phase (Part A) which enrolled a total of 5 cohorts of healthy subjects and a MAD phase (Part B) which enrolled 2 cohorts of healthy subjects. Two additional cohorts A6 and A7, were added following dose escalation analysis.

The planned optional Part C was to include a multiple-dose cohort of 25 subjects with suspected NASH and liver fibrosis (Cohort C1). However, Part C of the study was not performed as per Sponsor's decision.

Study Design

• Study Type: Interventional
• Actual Enrollment: 78 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Part A: 56 subjects will be studied in 7 cohorts (Cohorts A1 to A7) Part B: 22 subjects will be studied in 2 cohorts (Cohorts B1 to B2)Part A: 56 subjects will be studied in 7 cohorts (Cohorts A1 to A7) Part B: 22 subjects will be studied in 2 cohorts (Cohorts B1 to B2)
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Other
• Official Title: GB1211 - A Randomised, Double-Blind, Placebo-Controlled, First-In-Human, Study of Orally Administered GB1211 to Evaluate the Safety, Tolerability, and PK of Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) in Healthy Subjects
• Actual Study Start Date: Jan 14, 2019
• Actual Primary Completion Date: Jun 25, 2019
• Actual Study Completion Date: Jun 25, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A1 - 5 mg GB1211 single dose and Placebo 6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.	Drug: GB1211; Hard capsules for oral use
Experimental: A2 - 20 mg GB1211 single dose and Placebo 6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.	Drug: GB1211; Hard capsules for oral use
Experimental: A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo 6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.	Drug: GB1211; Hard capsules for oral use
Experimental: A4 - 100 mg GB1211 single dose and Placebo 6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.	Drug: GB1211; Hard capsules for oral use
Experimental: A5 - 200 mg GB1211 single dose and Placebo 6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.	Drug: GB1211; Hard capsules for oral use
Experimental: B1 - GB1211 multiple ascending doses, 50mg BID and Placebo GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.	Drug: GB1211; Hard capsules for oral use
Experimental: B2 - GB1211 multiple ascending doses, 100mg BID and Placebo GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..	Drug: GB1211; Hard capsules for oral use
Experimental: A6 - 50mg GB1211 single dose and Placebo 8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.	Drug: GB1211; Hard capsules for oral use
Experimental: A7 - 400 mg GB1211 single dose and Placebo 8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.	Drug: GB1211; Hard capsules for oral use
Experimental: Part A - Placebo for GB1211 In Part A - 2 subjects from each arm (A1-A5) will receive placebo.	Drug: Placebo; Hard capsules for oral use; Other Names: GB1211
Experimental: Part B - Placebo for GB1211 (BID) Part B - 3 subjects from each arm B1 and B2 will receive placebo.	Drug: Placebo; Hard capsules for oral use; Other Names: GB1211

Outcome Measures

Primary Outcome Measures

1. Number of Participants With of Adverse Events (AEs) [Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks]

   The number of participants in each arm that report Adverse Events (AEs)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 60 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Subjects for Parts A and B must satisfy all of the following criteria at the Screening visit unless otherwise stated:

1. Males or females, of any race, between 18 and 55 years of age (60 years for Part B), inclusive.

2. Body mass index (BMI) of 18.0 to 32.0 kg/m^2 (inclusive) with a minimum body weight of 50 kg.

3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations

4. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed further in the protocol.

5. Male subjects must agree to refrain from sperm donation and females should refrain from ova donation from the date of Check-in (Day -1) until 90 days after the Follow-up visit.

6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Subjects for Parts C must satisfy all of the following criteria at the Screening visit unless otherwise stated:

1. Males or females, of any race, between 18 and 60 years of age, inclusive.

2. Body mass index (BMI) of ≥ 25.0 and ≤ 38.0 kg/m^2.

3. Documented history of fatty liver within the last 24 weeks by one of the following: magnetic resonance imaging (MRI) suggesting liver fat ≥ 8%, ultrasound (US) indicating fatty liver, or Fibroscan Controlled Attenuation Parameter (CAP) > 270 dB/m. In subjects without a documented history of fatty liver, a Fibroscan CAP or US can be performed at Screening. Subjects with Fibroscan CAP > 270 dB/m or US indicating fatty liver are eligible.

4. Metabolic syndrome (Adult Treatment Panel III definition) or T2DM (defined as stable diabetes with glycosylated haemoglobin [HbA1c] ≤ 9.5%).

5. Alanine aminotransferase (ALT) ≥ 20 U/L for females and ≥ 30 U/L for males at Screening.

6. Fibroscan ≥ 7 KPa and < 13 KPa, or Fibrosis-4 (FIB-4) index ≥ 1.1 and <3.25.

7. Females of nonchildbearing potential defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) or postmenopausal (defined as at least 12 months postcessation of menses without an alternative medical cause and follicle-stimulating hormone [FSH] level ≥ 40 mIU/mL). Males will agree to use contraception as detailed in protocol.

8. Male subjects must agree to refrain from sperm donation and females should refrain from ova donation from the date of Check-in (Day -1) until 90 days after the Follow-up visit.

9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion Criteria:

Subjects from Part A & B will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).

2. History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.

3 (Part A). Any of the following: a. QTcF > 450 msec confirmed by repeat measurement. b. QRS duration > 110 msec confirmed by repeat measurement. c. PR interval > 220 msec confirmed by repeat measurement. d. findings which would make QTc measurements difficult or QTc data uninterpretable. e. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, family history of long QT syndrome).

3 (Part B). Clinically significant ECG abnormalities or QTcF greater than 450 msec for males and 470 msec for females at either Screening or Day 1 predose, or any prior history of QT abnormality.

1. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.

2. Positive hepatitis panel and/or positive human immunodeficiency virus (HIV) test.

3. Participation in a clinical study involving administration of an investigational agent or vaccine (new chemical entity) or having received a biological product in the past 90 days prior to dosing.

4. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the Investigator (or designee).

5. Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee).

6. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in, or positive cotinine at Screening or Check-in.

7. Receipt of blood products within 2 months prior to Check-in and donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.

8. Subject who, in the opinion of the Investigator (or designee), should not participate in this study.

Subjects from Part C will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

1. If diabetic and diabetes is other than T2DM.

2. Subjects, who have had bariatric surgery of any kind or, in the opinion of the Investigator, have experienced a clinically significant change in body weight within the 3 months prior to Screening.

3. History of any known serious disease (such as cancer, except skin basocellular carcinomas, major infection, clinically significant gastrointestinal disorder, major autoimmune disease) or other disease which in the Investigator's opinion would exclude the patient from the study.

4. The following clinical laboratory results at Screening: -Total Bilirubin > 2 × ULN, ALT > 155 U/L for females and > 185 U/L for males, AST > 155 U/L for females and > 200 U/L for males

5. Other abnormal clinical laboratory values that are considered clinically significant for this population.

6. Clinically significant ECG abnormalities or QTcF greater than 450 msec for males and 470 msec for females at either Screening or Day 1 predose, or any prior history of QT abnormality.

7. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in.

8. Alcohol consumption of > 14 units per week for males and for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.

9. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check-in.

10. Positive hepatitis panel and/or positive HIV test .

11. A creatinine clearance of less than 50 mL/min (as calculated by Cockcroft-Gault equation) or estimated glomerular filtration rate (eGFR) < 60 mL/[min*1.73 m²] at Screening.

12. Subject taking any antidiabetic medications, with the exception of metformin, sulfonylureas, gliptins, and sodium/glucose co-transporter 2 inhibitors, within 3 months prior to Screening.

13. Use of any of the following non-permitted medication within 6 months prior to Screening: amiodarone, bile salt chelators, methotrexate, pharmacological doses of systemic corticosteroids for at least 2 consecutive weeks, or any other medications known to affect liver function.

14. Have previously completed or withdrawn from this study investigating GB1211, and have previously received the investigational product.

15. Subject who, in the opinion of the Investigator (or designee), should not participate in this study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	(For Parts A and B) Covance Clinical Research Unit Ltd	Leeds		United Kingdom	LS2 9LH

Sponsors and Collaborators

• Galecto Biotech AB

Investigators

• Principal Investigator: Dr Ashley Brooks, MBChB, Covance
• Study Chair: Dr Bertil Lindmark MD PHD, Chief Medical Officer, Galecto Biotech AB

Study Documents (Full-Text)

• Statistical Analysis Plan - Jul 25, 2019
• Study Protocol - Nov 5, 2018

More Information

Publications

None provided.

• Responsible Party: Galecto Biotech AB
• ClinicalTrials.gov Identifier: NCT03809052
• Other Study ID Numbers: GB1211-001; 2018-003914-41; Covance Study Number: 8392356
• First Posted: Jan 18, 2019
• Last Update Posted: Mar 17, 2021
• Last Verified: Jan 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Galecto Biotech AB: GB1211; Phase 1; First Time in Human; Safety; Tolerability; Pharmacokinetics; Single Ascending Dose (SAD); Multiple Ascending Dose (MAD); Healthy Volunteers; Nonalcoholic Steatohepatitis (NASH); Liver Fibrosis

Study Results

Participant Flow

Recruitment Details	A total of 78 subjects entered the study and were randomised to treatment, with 56 subjects in Part A and 22 subjects in Part B.

Arm/Group Title	A1 - 5 mg GB1211 Single Dose	A2 - 20 mg GB1211 Single Dose	A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)	A4 - 100 mg GB1211 Single Dose	A5 - 200 mg GB1211 Single Dose	A6 - 50mg GB1211 Single Dose	A7 - 400 mg GB1211 Single Dose	Part A - Placebo GB1211	B1 - GB1211 Multiple Ascending Doses, 50mg BID	B2 - GB1211 Multiple Ascending Doses, 100mg BID	Part B - PLacebo GB1211 (BID)
Arm/Group Description	6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods. GB1211: Hard capsules for oral use	6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	In Part A, 14 subjects will receive placebo in total. Placebo: Hard capsules for oral use	GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	GB1211 100 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	In Part B, 6 subjects will receive placebo in total. Placebo: Hard capsules for oral use
Period Title: Overall Study
STARTED	6	6	6	6	6	6	6	14	8	8	6
COMPLETED	6	6	6	6	6	6	6	14	8	8	6
NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0

Baseline Characteristics

Arm/Group Title	A1 - 5 mg GB1211 Single Dose	A2 - 20 mg GB1211 Single Dose	A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)	A4 - 100 mg GB1211 Single Dose	A5 - 200 mg GB1211 Single Dose	A6 - 50mg GB1211 Single Dose	A7 - 400 mg GB1211 Single Dose	Part A - Placebo for GB1211	B1 - GB1211 Multiple Ascending Doses, 50mg BID	B2 - GB1211 Multiple Ascending Doses, 100mg BID	Part B - Placebo for GB1211 (BID)	Total
Arm/Group Description	6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	In Part A, 14 subjects will receive placebo in total. Placebo: Hard capsules for oral use Placebo: Hard capsules for oral use	GB1211 50mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	GB1211 100mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	In Part B, 6 subjects will receive placebo in total. Placebo: Hard capsules for oral use Placebo: Hard capsules for oral use	Total of all reporting groups
Overall Participants	6	6	6	6	6	6	6	14	8	8	6	78
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	34 (7.4)	38 (12.8)	28 (8.0)	35 (9.2)	36 (12.8)	34 (13.5)	39 (11.3)	37 (13.3)	42 (12.6)	37 (11.6)	39 (8.1)	36 (11.0)
Sex: Female, Male (Count of Participants)
Female	3 50%	2 33.3%	2 33.3%	1 16.7%	1 16.7%	2 33.3%	2 33.3%	6 42.9%	3 37.5%	3 37.5%	2 33.3%	27 34.6%
Male	3 50%	4 66.7%	4 66.7%	5 83.3%	5 83.3%	4 66.7%	4 66.7%	8 57.1%	5 62.5%	5 62.5%	4 66.7%	51 65.4%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Not Hispanic or Latino	6 100%	6 100%	6 100%	6 100%	6 100%	6 100%	6 100%	14 100%	8 100%	8 100%	6 100%	78 100%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	1 16.7%	1 16.7%	0 0%	1 16.7%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	3 3.8%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	1 16.7%	0 0%	0 0%	0 0%	1 16.7%	0 0%	3 21.4%	0 0%	0 0%	0 0%	5 6.4%
White	4 66.7%	4 66.7%	5 83.3%	5 83.3%	6 100%	5 83.3%	6 100%	11 78.6%	8 100%	8 100%	6 100%	68 87.2%
More than one race	1 16.7%	0 0%	1 16.7%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	2 2.6%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Weight (kilogram) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kilogram]	75.9 (7.27)	77.9 (19.03)	71.4 (7.87)	75.1 (13.94)	73.7 (11.61)	73.3 (16.72)	79.7 (12.63)	81.3 (12.82)	85.4 (17.20)	76.8 (9.52)	70.9 (13.24)	76.5 (12.9)
Height (centimeter) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [centimeter]	172.3 (10.31)	171.7 (9.65)	169.8 (5.00)	175.3 (5.20)	174.7 (8.45)	176.2 (12.86)	173.7 (8.12)	173.6 (10.26)	178.9 (7.62)	173.4 (4.21)	175.2 (5.71)	174.1 (7.9)
BMI (kg/m^2) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kg/m^2]	25.9 (4.48)	26.1 (3.91)	24.8 (2.73)	24.5 (4.63)	24.1 (3.25)	23.3 (2.86)	26.2 (1.90)	26.9 (3.06)	26.5 (3.78)	25.5 (2.35)	23.0 (3.50)	25.2 (3.3)

Outcome Measures

1. Primary Outcome

Title	Number of Participants With of Adverse Events (AEs)
Description	The number of participants in each arm that report Adverse Events (AEs)
Time Frame	Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks

Outcome Measure Data

Analysis Population Description

All subjects in part A and B were included in the safety populations. The safety population will include all subjects who received at least 1 dose of study treatment (GB1211 or placebo). Safety parameters will be listed and summarised using descriptive statistics. No formal statistical analysis of safety data is planned.

Arm/Group Title	A1 - 5 mg GB1211 Single Dose	A2 - 20 mg GB1211 Single Dose	A3 - 50 mg GB1211 Single Dose (Food Effect Cohort)	A4 - 100 mg GB1211 Single Dose	A5 - 200 mg GB1211 Single Dose	A6 - 50mg GB1211 Single Dose	A7 - 400 mg GB1211 Single Dose	Part A - Placebo for GB1211	B1 - GB1211 Multiple Ascending Doses, 50mg BID	B2 - GB1211 Multiple Ascending Doses, 100mg BID	Part B - Placebo for GB1211 (BID)
Arm/Group Description	6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods. GB1211: Hard capsules for oral use	6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use	6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	6 healthy subjects are administered 400 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use	In Part A, 14 subjects will receive placebo in total. Placebo: Hard capsules for oral use	GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	GB1211 100 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use	In Part B, 6 subjects will receive placebo in total. Placebo: Hard capsules for oral use
Measure Participants	6	6	6	6	6	6	6	14	8	8	6
Number [Count of Participants]	3 50%	1 16.7%	1 16.7%	1 16.7%	0 0%	2 33.3%	1 16.7%	5 35.7%	1 12.5%	4 50%	3 50%

Adverse Events

Time Frame	Up to 5-7 days post final dose (Part A: Single dose), Part B: 6-7 weeks
Arm/Group Title	Part A - Placebo for GB1211		Part A - Placebo GB1211 (Fed)		A1 - 5 mg GB1211 Single Dose		A2 - 20 mg GB1211 Single Dose		A3 - 50 mg GB1211 Single Dose (Period 1: Fasted)" and "A3- 50 mg GB1211 Single Dose (Period 2: Fed)		A6 - 50mg GB1211 Single Dose		A3- 50 mg GB1211 Single Dose (Fed)		A4 - 100 mg GB1211 Single Dose		A5 - 200 mg GB1211 Single Dose		A7 - 400 mg GB1211 Single Dose		Part B - Placebo for GB1211 (BID)		B1 - GB1211 Multiple Ascending Doses, 50mg BID		B2 - GB1211 Multiple Ascending Doses, 100mg BID
Arm/Group Description	In Part A, 14 subjects will receive placebo in total. Placebo: Hard capsules for oral use		In Part A, 2 subjects will receive placebo in total in a fed state. Placebo: Hard capsules for oral use		6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use		6 healthy subjects are administered 50 mg without sentinel dosing. Optional cohort, as was added following dose-escalation analysis. GB1211: Hard capsules for oral use		6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		6 healthy subjects are administered 400 mg of GB1211 capsules orally as a single dose in the fasted state. 1 subject will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. GB1211: Hard capsules for oral use		In Part B, 6 subjects will receive placebo in total. Placebo: Hard capsules for oral use		GB1211 50 mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use		GB1211 100mg administered orally twice daily over 10 days. 8 healthy subjects received GB1211. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule. GB1211: Hard capsules for oral use
All Cause Mortality
	Part A - Placebo for GB1211		Part A - Placebo GB1211 (Fed)		A1 - 5 mg GB1211 Single Dose		A2 - 20 mg GB1211 Single Dose		A3 - 50 mg GB1211 Single Dose (Period 1: Fasted)" and "A3- 50 mg GB1211 Single Dose (Period 2: Fed)		A6 - 50mg GB1211 Single Dose		A3- 50 mg GB1211 Single Dose (Fed)		A4 - 100 mg GB1211 Single Dose		A5 - 200 mg GB1211 Single Dose		A7 - 400 mg GB1211 Single Dose		Part B - Placebo for GB1211 (BID)		B1 - GB1211 Multiple Ascending Doses, 50mg BID		B2 - GB1211 Multiple Ascending Doses, 100mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Serious Adverse Events
	Part A - Placebo for GB1211		Part A - Placebo GB1211 (Fed)		A1 - 5 mg GB1211 Single Dose		A2 - 20 mg GB1211 Single Dose		A3 - 50 mg GB1211 Single Dose (Period 1: Fasted)" and "A3- 50 mg GB1211 Single Dose (Period 2: Fed)		A6 - 50mg GB1211 Single Dose		A3- 50 mg GB1211 Single Dose (Fed)		A4 - 100 mg GB1211 Single Dose		A5 - 200 mg GB1211 Single Dose		A7 - 400 mg GB1211 Single Dose		Part B - Placebo for GB1211 (BID)		B1 - GB1211 Multiple Ascending Doses, 50mg BID		B2 - GB1211 Multiple Ascending Doses, 100mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Other (Not Including Serious) Adverse Events
	Part A - Placebo for GB1211		Part A - Placebo GB1211 (Fed)		A1 - 5 mg GB1211 Single Dose		A2 - 20 mg GB1211 Single Dose		A3 - 50 mg GB1211 Single Dose (Period 1: Fasted)" and "A3- 50 mg GB1211 Single Dose (Period 2: Fed)		A6 - 50mg GB1211 Single Dose		A3- 50 mg GB1211 Single Dose (Fed)		A4 - 100 mg GB1211 Single Dose		A5 - 200 mg GB1211 Single Dose		A7 - 400 mg GB1211 Single Dose		Part B - Placebo for GB1211 (BID)		B1 - GB1211 Multiple Ascending Doses, 50mg BID		B2 - GB1211 Multiple Ascending Doses, 100mg BID
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/14 (35.7%)		1/2 (50%)		3/6 (50%)		1/6 (16.7%)		1/6 (16.7%)		1/6 (16.7%)		1/6 (16.7%)		1/6 (16.7%)		0/6 (0%)		1/6 (16.7%)		1/6 (16.7%)		4/8 (50%)		3/8 (37.5%)
Gastrointestinal disorders
Constipation	1/14 (7.1%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/8 (0%)		2/8 (25%)
Diarrhoea	0/14 (0%)		0/2 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Dry mouth	1/14 (7.1%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Dyspepsia	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Abdominal distension	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		1/8 (12.5%)
Abdominal pain	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/8 (0%)		0/8 (0%)
Abdominal pain upper	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		1/8 (12.5%)
General disorders
Medical device site reaction	0/14 (0%)		0/2 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Pain	0/14 (0%)		0/2 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Infections and infestations
Nasopharyngitis	0/14 (0%)		0/2 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Injury, poisoning and procedural complications
Wound	1/14 (7.1%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Limb injury	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/8 (12.5%)		0/8 (0%)
Metabolism and nutrition disorders
Decreased appetite	1/14 (7.1%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Musculoskeletal and connective tissue disorders
Back pain	0/14 (0%)		0/2 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Arthralgia	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		1/8 (12.5%)
Pain in extremity	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		1/8 (12.5%)
Nervous system disorders
Headache	1/14 (7.1%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		4/8 (50%)		0/8 (0%)
Renal and urinary disorders
Pollakiuria	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		2/8 (25%)
Dysuria	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/8 (12.5%)		0/8 (0%)
Reproductive system and breast disorders
Menstruation irregular	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/8 (12.5%)		0/8 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Skin and subcutaneous tissue disorders
Dry Skin	0/14 (0%)		1/2 (50%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/8 (0%)		0/8 (0%)
Rash	0/14 (0%)		0/2 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		0/6 (0%)		1/6 (16.7%)		0/6 (0%)		0/8 (0%)		0/8 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.